Targeting Bruton's tyrosine kinase in B cell malignancies
- PMID: 24658273
- DOI: 10.1038/nrc3702
Targeting Bruton's tyrosine kinase in B cell malignancies
Abstract
Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies. Small-molecule inhibitors of BTK have shown antitumour activity in animal models and, recently, in clinical studies. High response rates were reported in patients with chronic lymphocytic leukaemia and mantle cell lymphoma. Remarkably, BTK inhibitors have molecular effects that cannot be explained by the classic role of BTK in BCR signalling. In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.
Similar articles
-
Role of Bruton's tyrosine kinase in B cells and malignancies.Mol Cancer. 2018 Feb 19;17(1):57. doi: 10.1186/s12943-018-0779-z. Mol Cancer. 2018. PMID: 29455639 Free PMC article. Review.
-
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.Clin Pharmacol Ther. 2015 May;97(5):455-68. doi: 10.1002/cpt.85. Epub 2015 Apr 3. Clin Pharmacol Ther. 2015. PMID: 25669675 Review.
-
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.Arch Pharm (Weinheim). 2018 Jul;351(7):e1700369. doi: 10.1002/ardp.201700369. Epub 2018 May 9. Arch Pharm (Weinheim). 2018. PMID: 29741794 Review.
-
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.J Clin Oncol. 2014 Jun 10;32(17):1830-9. doi: 10.1200/JCO.2013.53.1046. Epub 2014 Apr 28. J Clin Oncol. 2014. PMID: 24778403 Free PMC article.
-
Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.Clin Pharmacol Ther. 2015 May;97(5):469-77. doi: 10.1002/cpt.65. Epub 2015 Jan 20. Clin Pharmacol Ther. 2015. PMID: 25670208 Review.
Cited by
-
Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells.Front Pharmacol. 2022 Sep 9;13:894535. doi: 10.3389/fphar.2022.894535. eCollection 2022. Front Pharmacol. 2022. PMID: 36160379 Free PMC article.
-
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.Clin Pharmacokinet. 2019 May;58(5):659-672. doi: 10.1007/s40262-018-0725-7. Clin Pharmacokinet. 2019. PMID: 30556110 Clinical Trial.
-
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):489-499. doi: 10.1002/psp4.12408. Epub 2019 May 12. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31044521 Free PMC article.
-
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.J Immunother Cancer. 2022 Jan;10(1):e003551. doi: 10.1136/jitc-2021-003551. J Immunother Cancer. 2022. PMID: 35086945 Free PMC article. Review.
-
Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.Clin Cancer Res. 2014 Oct 15;20(20):5182-93. doi: 10.1158/1078-0432.CCR-14-0497. Clin Cancer Res. 2014. PMID: 25320368 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources